Clinical trial

Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

NCT01440101

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2010-11-01

PhasePHASE2 / PHASE3

Study timeline

Study start (unknown)2010-11-01Date precision: month

Registry last updated2014-10-21

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Multiple Sclerosisunresolved

Interventions

Natalizumab (BG00002)DRUG

PlaceboDRUG

Sponsors & collaborators

Biogenlead sponsor

Mapped research locations

TokyoJapan1 OsakaJapan1 FukuokaJapan1 KyotoJapan1 ChibaJapan1 HiroshimaJapan1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01440101 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.